


sequences appearing at pages 36 and 37 of the specification as filed. In view of the above amendments and the additional submissions provided herewith, it is respectfully submitted that the present application is in full compliance with the collective requirements of 37 C.F.R. §§ 1.821 through 1.825. Accordingly, Applicants respectfully submit that the application is now in condition for examination, and solicit such action at an early date. If there is any question which might be resolved by a telephone interview, the Examiner is invited to telephone the undersigned at (650) 298-5884.

Respectfully submitted,

By:



Christopher M. Holman
Attorney for Applicants
Reg. No. 40,021

January 17, 2002

MAXYGEN, INC.
515 Galveston Drive
Redwood City, California 94063
(650) 298-5884
(650) 298-4556 (fax)



MARKED UP COPY OF REPLACEMENT PARAGRAPH

SVBV promoter fragment was isolated by PCR amplification using oligonucleotide primer (5' CAAAGAAGAAGCTTAAGTATGC3' (SEQ ID NO:9) and 5' TGC GGGATCCGGTTTGTAAGCAGGGAGG3' (SEQ ID NO:10)) specific to sequences flanking the promoter region. Using this method, a 0.4 Kb promoter fragment consisting of sequences 6816 to 7291 of the SVBV-E3 genome was isolated (SEQ ID NO:1). The 3' end of the promoter fragment contains the un-translated leader sequences of ORF VII to ensure translatability of coding regions located downstream.